Redeye provides a first comment to the hugely disappointing and surprising regulatory update from the FDA, which issued a complete response letter (CRL) to Orphazyme.
ANNONS
Redeye provides a first comment to the hugely disappointing and surprising regulatory update from the FDA, which issued a complete response letter (CRL) to Orphazyme.